Tag:

GlaxoSmithKline

Latest Headlines

Latest Headlines

Glaxo quietly edges toward Ebola vaccine but clinical barriers remain

As Africa continues to experience the most severe Ebola outbreak in the disease's short history, the World Health Organization has deemed it ethical to offer unregistered interventions as potential treatments or preventive therapies, including investigational vaccines.

Health Canada signs off on GSK's plans to improve its flu vaccine plant

GlaxoSmithKline has submitted its plans to whip its troubled Quebec flu vaccine plant into shape to Health Canada, and the regulator says the action outline is up to snuff.

Researchers retract narcolepsy study linked to Glaxo's Pandemrix

Scientists thought they may have been on to something as far as deciphering the link between GlaxoSmithKline's pandemic swine flu vaccine and narcolepsy. But now, unable to replicate their findings, they've retracted the study.

Syria broadens corruption accusations against GlaxoSmithKline

Last month, a whistleblower sent a letter to GlaxoSmithKline alleging "multiple corrupt and illegal practices" in the company's Syrian consumer health operation before it was shut down in 2012. Now it appears the problems may have extended to GSK's prescription drug business in Syria, which is still in operation.

Glaxo: Ebola vaccine could be ready by 2015

British drugmaker GlaxoSmithKline says it is ready to begin clinical trials on an Ebola vaccine later this year and could have the vaccine available by 2015.

Can GlaxoSmithKline go from 0 to 150 on an Ebola vaccine program?

It took GlaxoSmithKline 30 years to get its new malaria vaccine ready for regulatory review. But global health officials--driven by a worldwide clamor--are excitedly pointing to GSK now as one of its prime candidates for getting a vaccine to fight Ebola in a matter of months.

FT sources: RBS' Hampton top contender to succeed Glaxo chair

A bribery scandal in China, with other probes ongoing in the Middle East and Europe. Mounting competition to declining top drug Advair. And so-far-lackluster launches of the products tabbed as future respiratory stars. So, who wants to be GlaxoSmithKline's next chairman?

UPDATED: GSK's private eye sentenced to 2.5 years in Chinese prison

China finally has a verdict on the husband-wife investigator team linked to GlaxoSmithKline's bribery scandal: U.K. citizen Peter Humphrey is headed for 2.5 years behind bars, and his American wife, Yu Yingzeng, will get 2 years, Pharmafile reports.

GlaxoSmithKline backs off from Galapagos' anti-inflammatory hopeful

GlaxoSmithKline has again scaled back its expectations for an anti-inflammatory treatment licensed from Galapagos, calling off any plans for late-stage study after a few Phase II miscues dulled the drug's potential.

Pfizer needs to ink a big deal, pronto. GSK or Actavis, maybe?

A couple of things happened this past week to set off new chatter about a Pfizer megadeal. First, GlaxoSmithKline posted disappointing earnings and cut its full-year forecast, sending its stock into the dumpster--and its market cap tumbling. Then, Berenberg analysts issued an investor note extolling the potential virtues of a Pfizer-GlaxoSmithKline combo. Let the speculation continue.